Table 1.

Demographic and clinical characteristics

	Before matching					After matching
Characteristic	Anti-PD-1 plus Sorafenib (n = 58)		Anti-PD-1 alone (n = 82)		p value	Anti-PD-1 plus sorafenib (n = 58)		Anti-PD-1 alone (n = 42)		p value
Age (mean ± SD)	69.1 ± 13.4		61.7 ± 12.3		0.25	69.1 ± 13.4		61.2 ± 12.7		0.25
Male	45	77.6%	64	78.0%	0.95	45	77.6%	29	69.0%	0.77
Etiology
HBV	35	60.3%	53	64.6%	0.61	35	60.3%	28	66.7%	0.52
HCV	9	15.5%	15	18.3%	0.67	9	15.5%	8	19.0%	0.64
Alcohol	29	50.0%	36	43.9%	0.48	29	50.0%	18	42.9%	0.48
Cirrhosis	21	36.2%	26	31.7%	0.58	21	36.2%	17	40.5%	0.66
Child-Pugh score
A	47	81.0%	66	80.5%	0.94	47	81.0%	29	69.0%	0.17
B	11	19.0%	16	19.5%		11	19.0%	13	31.0%
ALBI grade
Grade 1	10	17.2%	31	37.8%	< 0.05	10	17.2%	12	28.6%	0.34
Grade 2	41	70.7%	47	57.3%		41	70.7%	27	64.3%
Grade 3	7	12.1%	4	4.9%		7	12.1%	3	7.1%
BCLC stage
B	3	5.2%	15	18.3%	< 0.05	3	5.20%	3	7.1%	0.68
C	55	94.8%	67	81.7%		55	94.8%	39	92.9%
PVT	43	74.1%	38	46.3%	< 0.05	43	74.1%	29	69.0%	0.58
Metastasis	30	51.7%	49	59.8%	0.35	30	51.7%	26	61.9%	0.31
AFP > 400 (ng/mL)	34	58.6%	43	52.4%	0.47	34	58.6%	29	69.0%	0.29
Sorafenib experienced	37	63.8%	49	59.8%	0.63	37	63.8%	28	66.7%	0.31

PVT portal vein thrombosis